Kronos Bio Stock Today

KRON Stock  USD 1.05  0.02  1.87%   

Performance

4 of 100

 
Weak
 
Strong
Insignificant

Odds Of Distress

Over 85

 
High
 
Low
Very High
Kronos Bio is selling at 1.05 as of the 10th of December 2024; that is 1.87 percent decrease since the beginning of the trading day. The stock's open price was 1.07. Kronos Bio has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 10th of November 2024 and ending today, the 10th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
9th of October 2020
Category
Healthcare
Classification
Health Care
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company was incorporated in 2017 and is headquartered in San Mateo, California. Kronos Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 60.34 M outstanding shares of which 520.99 K shares are now shorted by private and institutional investors with about 8.81 trading days to cover. More on Kronos Bio

Moving against Kronos Stock

  0.38SLS Sellas Life SciencesPairCorr
  0.31GILD Gilead SciencesPairCorr

Kronos Stock Highlights

CEO PresidentNorbert Bischofberger
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.02360.0265
Fairly Down
Slightly volatile
Total Current Liabilities14.1 M24.7 M
Way Down
Slightly volatile
Non Current Liabilities Total35.5 M29.5 M
Fairly Up
Slightly volatile
Total Assets279.9 M213.3 M
Significantly Up
Slightly volatile
Total Current Assets237.3 M178.8 M
Significantly Up
Slightly volatile
Debt Levels
Kronos Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kronos Bio's financial leverage. It provides some insight into what part of Kronos Bio's total assets is financed by creditors.
Liquidity
Kronos Bio currently holds 28.27 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Kronos Bio has a current ratio of 14.77, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kronos Bio's use of debt, we should always consider it together with its cash and equity.

Begin Period Cash Flow

104.99 Million
Kronos Bio (KRON) is traded on NASDAQ Exchange in USA. It is located in 1300 South El Camino Real, San Mateo, CA, United States, 94402 and employs 58 people. Kronos Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 64.56 M. Kronos Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 60.34 M outstanding shares of which 520.99 K shares are now shorted by private and institutional investors with about 8.81 trading days to cover. Kronos Bio currently holds about 267.89 M in cash with (78.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Kronos Bio Probability Of Bankruptcy
Ownership Allocation
Kronos Bio maintains a total of 60.34 Million outstanding shares. Kronos Bio holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Kronos Ownership Details

Kronos Stock Institutional Holders

InstituionRecorded OnShares
Jacobs Levy Equity Management, Inc.2024-09-30
406.8 K
Woodline Partners Lp2024-09-30
309.6 K
Choate Investment Advisors2024-09-30
308.7 K
Gentrust, Llc2024-09-30
295.2 K
Cm Management, Llc2024-09-30
200 K
Two Sigma Advisers, Llc2024-09-30
175.4 K
State Street Corp2024-09-30
171.2 K
Kennedy Capital Management Inc2024-09-30
137.2 K
Casdin Capital, Llc2024-09-30
123.8 K
Vida Ventures Advisors, Llc2024-09-30
2.8 M
Millennium Management Llc2024-09-30
M
View Kronos Bio Diagnostics

Kronos Bio Historical Income Statement

At this time, Kronos Bio's Non Operating Income Net Other is very stable compared to the past year. View More Fundamentals

Kronos Stock Against Markets

Kronos Bio Corporate Management

Christopher DinsmoreStrategic AdvisorProfile
Stephanie YaoExec CommunicationsProfile
Barbara JDStrategic AdvisorProfile
Marni KottleSr RelationsProfile
Rocio HoyosSenior ManagementProfile
Joshua KazamCoFounder DirectorProfile
Sandra GardinerInterim OfficerProfile
When determining whether Kronos Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kronos Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kronos Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kronos Bio Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.143
Quarterly Revenue Growth
0.442
Return On Assets
(0.28)
Return On Equity
(0.63)
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.